Our study has major strengths, including the use of analytically validated antibodies, predefined scoring criteria (CD163 and CAIX), and the use of an independent cohort (cohort I) to confirm the performance of G-CSF as a biomarker on breast cancer tissue microarrays. Here, CD163 is linked to breast cancer.